News Release 

Researchers identify genes behind uterine leiomyosarcoma

Yale University

Research News

New Haven, Conn. -- In a new study, Yale Cancer Center researchers have defined the genetic landscape of uterine leiomyosarcomas (uLMS). Furthermore, using fully sequenced patient-derived xenografts, the team has preclinically validated new treatment modalities, which may point to new treatments for uterine cancer. Study results were published online in an early edition of the Proceedings of the National Academy of Science (PNAS).

Uterine cancer is the most common gynecologic malignancy and uterine leiomyosarcomas (uLMS) are highly lethal sarcomas arising from the myometrium, the smooth muscle layer of the uterus. They represent the most common type of uterine sarcomas, which overall account for three to seven percent of all uterine cancers. uLMS have poor prognosis and are characterized by aggressive biological behavior leading to early local and distant metastatic spread.

A collaborative team--which included researchers with expertise in gynecological cancer, genomics, pathology, pharmacology, and computational biology from the United States of America, South Korea, Spain, and Italy-- identified a number of genes that are frequently mutated in uLMS. Using an integrated and comprehensive genetic approach, scientists identified multiple genes with recurrent alterations in uLMS including the homologous-recombination DNA-repair deficiency (HRD), the alternative lengthening of telomere (ALT), C-MYC/BET, and PI3K-AKT-mTOR pathway as potential targets.

"Using two fully sequenced patient-derived-xenografts (PDXs) harboring deranged C-MYC/BET and PTEN/PIK3CA pathways and/or an HRD signature, we found olaparib (PARPi), GS-626510 (BETi), and copanlisib (PIK3CAi) monotherapy to significantly inhibit in vivo uterine leiomyosarcomas growth," said senior author of the study Alessandro Santin, MD, Professor of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine and Disease Aligned Research Team Leader for the Gynecological Cancers Program at Yale Cancer Center and Smilow Cancer Hospital. "Our integrated genetic analysis combined with in vivo preclinical validation experiments suggests that a large subset of uLMS may potentially benefit from existing PARPi/BETi/PIK3CAi targeted drugs."

The team reported results from 83 women diagnosed with uLMS from the U.S. and Italy to determine the molecular basis of the tumor's aggressive behavior. They sequenced the genes from the tumors and identified mutations that are crucial for these tumors to grow. The team also studied the copy number variations--genes that are not mutated but are amplified in the tumors to give them a growth advantage over normal tissues as well as tumor RNA expression levels and gene fusion products.

"The establishment of 2 PDXs with different mutation profiles provided the opportunity for in vivo assessment of whether a mutation profile is predictive of drug response," said corresponding author Joseph Schlessinger, PhD, William H. Prusoff Professor and Chairman of the Department of Pharmacology at Yale School of Medicine and Co-Director of the Yale Cancer Biology Institute. "These preclinical validation studies have suggested new opportunities for personalized therapy."

###

Other authors of the study include Jungmin Choi, Aranzazu Manzano, Weilai Dong and Stefania Bellone, Elena Bonazzoli, Luca Zammataro, Siming Zhao, Gulden Menderes, Gary Altwerger, Burak Zeybek, Natalia Buza, Pei Hui, Antonella Ravaggi, Eliana Bignotti, Chiara Romani, Paola Todeschini, Laura Zanotti, Franco Odicino, Sergio Pecorelli, Laura Ardighieri, Kaya Bilguvar, Ludmil B Alexandrov, Xiaotong Yao, Aditya Deshpande, Samir Zaidi, Adele Guglielmi, Barbara Gnutti, Nupur Nagarkatti, Joan R. Tymon-Rosario, Justin Harold, Dennis Mauricio, Kyungjo Jeong, Charles M. Quick, Vaagn Andikyan, Mitchell Clark, Marcin Imielinski, Dan-Arin Silasi, Gloria S. Huang, Elena Ratner, Masoud Azodi, Peter E. Schwartz, and Richard P. Lifton.

The research was supported as part of a collaborative program with Gilead Sciences, Inc. The study was also funded in part by grants from the National Institutes of Health, the National Cancer Institute, the Deborah Bunn Alley Ovarian Cancer Research Foundation, The Honorable Tina Brozman Foundation, the Discovery to Cure Foundation, the Stand Up to Cancer Foundation, the Guido Berlucchi Foundation, and the Domenic Cicchetti Foundation.

About Yale Cancer Center and Smilow Cancer Hospital

Yale Cancer Center (YCC) is one of only 51 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive cancer centers play a vital role in the advancement of the NCI's goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.